MDS 2023 | Patient-reported outcome measures for MDS: EORTC QLQ-C30 & QUALMS
Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, briefly discusses commonly used patient-reported outcome (PRO) measures for patients with myelodysplastic syndromes (MDS), commenting on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) tool, and the recently validated Quality of Life in Myelodysplasia Scale (QUALMS). This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy/Advisory Board: Abbvie, Syros, Incyte, Janssen
